Pharma Generics

Pharma Generics
Components Market Cap/Price Change

4 components without market cap not shown.

Period Return
23.4%
Return Rank
Strong
Risk Exposure
Average Risk

The rise and fall of Israeli industry leader Teva , reaching 69$ at the end of May 2015 only to fall off a cliff by August 2017,  and  settling  in a low range between $8 and $10 since three years, a story of extreme challenges buffeting the generics pharma industry

With aging populations in most developed countries, exploding healthcare costs and creaking insurance systems, and with better health coverage coming to the emerging markets, generics are strongly supported by national and local health authorities

But national as well as private health insurers press for more control over healthcare expenses. Increased competition, with more FDA approved generics brought on the US market every year, and sharper negotiations point towards commoditization and margin pressure

The October 2023 spin-off by Novartis , setting up Sandoz as alone-standing generics pharmaceutical firm, can be understood in this context

Theme Components
Name
Ticker
Sector
Industry
Cur. Price
Mkt. Cap
Performance
Momentum
Risk Rank
Risk Contrib
 
Perrigo PRGO Health CareDrug Manufacturers - Generic16.942.3 B51.2% Strong Up Above Average
Teva Pharmaceutical Industries TEVA Health CareDrug Manufacturers - Generic42.2349 B74.4% Strong Up Below Average
Hypermarcas (ADR) HYPMY Health CareDrug Manufacturers - Generic3.70--19.8% Sharp Down Above Average
Hikma Pharmaceuticals (ADR) HKMPY Health CareDrug Manufacturers - Generic45.35-8.3% Neutral Below Average
Sandoz Group (ADR) SDZNY Health CareDrug Manufacturers - Generic95.61-40.7% Neutral Below Average
Abbott Laboratories ABT Health CareDrug Manufacturers - Diversified104.48182 B-15.5% Neutral Below Average
Bausch Health Companies BHC Health CareDrug Manufacturers - Diversified8.733.2 B44.8% Strong Up Above Average
Fresenius (ADR) FSNUY Health CareHealthcare Facilities & Services14.02-3.2% Weak Up Low Risk
1 – 8 of 8